Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients

NCT02451462 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT02451462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02451462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients
Lead sponsor
Stanford University
Phase
Not applicable
Overall status
Withdrawn
Start date
September 30, 2015
Completion date
September 30, 2018
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow transplant, hematopoietic stem cell transplant